Skip to main content
. 2020 Aug 29;14(1):243–248. doi: 10.1007/s13193-020-01188-2

Table 1.

Patient and tumor characteristics

Characteristic CBS (254) no. (%) MRM (180) no. (%) P value
Age
  < 50 92 (36.2) 118 (65.6) 0.000
  ≥ 50 162 (63.8) 62 (34.4)
Menopausal status
  Premenopausal 96 (37.8) 118 (65.6) 0.000
  Perimenopausal 42 (16.5) 26 (14.4)
  Postmenopausal 116 (45.7) 36 (20.0)
Pathology
  IDC 245(96.5) 173 (96.1) 0.793
  Lobular 4 (1.5) 2 (1.1)
  Medullary 5 (2.0) 5 (2.8)
T stage
  1 42 (23.3) 77 (29.9) 0.079
  2 138 (76.7) 177 (70.1)
N stage
  0 138(54.3) 113 (62.8) 0.049
  1 116 (45.7) 67 (37.2)
Grade
  1 6 (2.3) 2 (1.1) 0.348
  2 234 (92.1) 172 (95.6)
  3 14 (5.5) 6 (3.3)
ER
  Positive 168 (66.1) 106 (58.9) 0.075
  Negative 86 (33.9) 74 (41.1)
PR 0.070
  Positive 138 (54.3) 84 (46.7)
  Negative 116 (45.7) 96 (53.3)
HER2
  Positive 51 (20.1) 42 (10.5)
  Negative 190 (74.8) 131 (81.9)
  Unknown 13 (5.11) 7 (28.6) 0.630
TNBC 67 (15.4) 55 (12.7)

CBS conservative breast surgery

MRM modified radical mastectomy

IDC infiltrating duct carcinoma

TNBC triple negative breast cancer